Answers are grounded in this paper and cite their sources.
Introduction Cholestatic liver injury (CLI) is characterized by the accumulation of toxic bile acids (BAs) and lacks effective therapeutic agents in clinical practice. Salvianolic acid C (SAC) is a hepatoprotective polyphenol, but its efficacy in treating BA metabolic disorders and the underlying mechanism remain unclear. We investigated the protective effect of SAC in α-naphthyl isothiocyanate (ANIT)-induced CLI in rats. Methods SAC (10, 20 mg/kg) was administered by gavage daily for 7 days, with ANIT administered by gavage on day 5. Results SAC improved liver function, attenuated hepatic oxidative stress and inflammation, and reduced necrosis and inflammatory infiltration. Serum BA profiling showed that SAC remodeled BA profiles, with changes in DCA, LCA, β-MCA, Tα-MCA, and UDCA-3S. Bio-layer interferometry (BLI) assays showed that SAC binds with favorable affinity to BA metabolism-related receptors (FXR, PPARα, and FGFR4). Western blotting and immunofluorescence further confirmed that SAC regulates the expression of these target proteins. In addition, SAC upregulated the protein levels of FXR, SHP, PPARα, FGFR4, BSEP, ABCB4, Nrf2, GPX4, and FTH1, while downregulating those of CYP7A1, CYP8B1, IL-6R, NF-κB p65, JAK2, STAT3, and HO-1, and reducing 4-HNE levels. Discussion These findings suggest that SAC protects against ANIT-induced CLI, possibly by regulating BA homeostasis, inflammatory responses, and oxidative stress.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: